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Reduced expression of the murine 
HLA-G homolog Qa-2 is associated 
with malignancy, epithelial-
mesenchymal transition and 
stemness in breast cancer cells
Istéfani L. da Silva1,2,3, Lucía Montero-Montero3, Ester Martín-Villar3,4, Jorge Martin-Pérez3, 
Bruno Sainz3,5, Jaime Renart3, Renata Toscano Simões6, Émerson Soares Veloso1,  
Cláudia Salviano Teixeira7, Mônica C. de Oliveira7, Enio Ferreira1 & Miguel Quintanilla3
Qa-2 is believed to mediate a protective immune response against cancer; however, little is known 
about the role of Qa-2 in tumorigenesis. Here, we used 4T1 breast cancer cells to study the involvement 
of Qa-2 in tumor progression in a syngeneic host. Qa-2 expression was reduced during in vivo tumor 
growth and in cell lines derived from 4T1-induced tumors. Tumor-derived cells elicited an epithelial-
mesenchymal transition associated with upregulation of Zeb1 and Twist1/2 and enhanced tumor 
initiating and invasive capacities. Furthermore, these cells showed increased stem characteristics, as 
demonstrated by upregulation of Hes1, Sox2 and Oct3/4, and enrichment of CD44high/CD24median/low  
cells. Remarkably, Qa-2 cell-surface expression was excluded from the CD44high/CD24median/low 
subpopulation. Tumor-derived cells showed increased Src activity, and treatment of these cells with the 
Src kinase inhibitor PP2 enhanced Qa-2 but reduced Sox2 and CD44high/CD24median/low expression levels, 
suggesting that Src signaling, while positively associated with stemness, negatively regulates Qa-2 
expression in breast cancer. Finally, overexpression of the Qa-2 family member Q7 on the cell surface 
slowed down in vivo tumor growth and reduced the metastatic potential of 4T1 cells. These results 
suggest an anti-malignant role for Qa-2 in breast cancer development, which appears to be absent from 
cancer stem cells.
HLA-G belongs to the human non-classical major histocompatibility complex (MHC), or MHC class 1b, that has 
been shown to be involved in the immune recognition of tumors1, 2. The genes encoding MHC class 1b antigens 
are oligomorphic, which grants an advantage with respect to the highly polymorphic MHC class 1a antigens in 
order to develop cancer immunotherapies directed to a wider patient population3. In this respect, it is important 
to understand the role MHC class 1b proteins play in cancer development and progression. Qa-2 is believed to 
be the murine homolog of HLA-G, as both families of proteins share a number of characteristics, including: i, the 
presence of membrane-bound and soluble forms that arise from alternative splicing; ii, their involvement in pre-
implantation embryo development; and iii, their immunoregulatory roles2. There are four main Qa-2 loci: Q6, Q7, 
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Q8 and Q9, which are present in different combinations in each mouse haplotype. The Q7 gene is almost identical 
to Q9, and Q6 is very similar to Q8. Therefore, these genes are referred as Q7/Q9 and Q6/Q8 pairs4.
It has been found that HLA-G expression is enhanced in a number of tumors, including different types of 
lymphomas and leukemias, melanoma, and breast, kidney, ovarian, lung and colorectal carcinomas5. Moreover, 
HLA-G expression is considered a bad prognostic factor in different types of solid tumors, including colorectal 
and breast cancers5–7. Whereas most studies have linked HLA-G expression with tumor immune evasion due to 
its interaction with inhibitory receptors on immune cells5, 8–10, other reports suggest that HLA-G can activate NK 
cells and promote cytotoxicity because of its interaction with the KIR2DL4 receptor11, 12. However, these results 
are controversial as both inhibitory and stimulatory functions have been reported for KIR2DL4, and it is unclear 
that HLA-G binds KIR2DL4 on NK cells in the tumor microenvironment2, 5. To date, however, only a handful 
studies have addressed the role of Qa-2 in cancer, and most of these studies have focused on Q9. Q9 expression is 
downregulated in cell lines derived from tumors, such as melanoma, hepatoma, mastocytoma and lymphoma13, 14, 
and has been involved in tumor rejection of melanoma, Lewis lung carcinoma and T-cell lymphoma14–16.
In this report, we used a 4T1 murine mammary carcinoma syngeneic model to analyze the expression of Qa-2 
during in vivo breast cancer cell growth and in tumor cells lines derived from these tumors. 4T1 cells are a useful 
model for advanced human breast cancer or highly metastatic triple-negative carcinomas17–19. The role of Q7 in 
4T1 tumor formation and metastasis was also assessed. Our results suggest an anti-tumor function for Qa-2 in 
breast cancer.
Results
Qa-2 expression levels decrease during tumor formation. In order to evaluate whether Qa-2 expres-
sion changes during breast cancer development, 4T1 cells were intradermally (i.d.)/subcutaneously (s.c.) injected 
into the left flank of syngeneic Balb/c mice and tumors harvested at 10, 17 and 24 days post-injection. At these 
post-injection times, the mean volumes of tumors were 1.47 ± 0.75, 1.93 ± 0.68 and 4.61 ± 1.66 cm3, respectively. 
Qa-2 expression in neoplastic and peritumor inflammatory cells was determined by immunohistochemistry, 
whereas soluble Qa-2 concentrations in the sera of the animals were scored by ELISA. The presence of Qa-2 in 
tumors was focal (Fig. 1A–C). The number of neoplastic cells that stained positive for Qa-2 was, in general, low, 
and never exceeded 25% of the total number of tumor cells. Moreover, a clear observable and significant decrease 
in Qa-2 expression in neoplastic cells was associated with tumor expansion (Fig. 1D). The number of peritumor 
inflammatory Qa-2-positive cells and the amount of soluble Qa-2 were also reduced during tumor growth; how-
ever, these differences were not statistically significant (Fig. 1E,F).
Figure 1. Qa-2 expression decreases during tumor growth. (A–C) Immunohistochemical detection of Qa-2 in 
4T1-induced tumors at 10 (A), 17 (B) and 24 (C) days post-inoculation. Examples of stained tumor cells and 
peritumor inflammatory cells are indicated by arrows and arrowheads, respectively. Groups of mice (n = 15) 
were inoculated i.d./s.c. with 106 cells into the left flank. Bars, 20 μm. (D,E) Estimation of neoplastic (D) and 
peritumor inflammatory (E) cells stained for Qa-2. Values represent the average number of tumor cells stained 
for Qa-2 determined in 15 fields. A number of 5 tumors per each post-injection time were evaluated. Asterisk 
indicates statistically significant difference (*p < 0.05). (F) The concentration of soluble Qa-2 in the sera of mice 
bearing 4T1 tumors and control mice without tumors at different days post-injection, as determined by ELISA. 
Values represent the average of 5 mice per group at each post-inoculation time.
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Transplantation in vivo selects for 4T1 cells with enhanced fibroblastic, malignant and stem 
characteristics. Primary tumors were induced by injection of 4T1 cells either i.d./s.c. into the back or, ortho-
topically, into the mammary fat pad of Balb/c mice. Compared to 4T1 parental cells, tumor-derived cells, par-
ticularly 4T1t cells, showed a more elongated morphology and a higher number of detached (stringent) cells, as 
determined by microscopic examination (Fig. 2A, insets). While 4T1t cells were less proliferative than 4T1m and 
4T1 cells in vitro (Supplementary Fig. S1), they showed increased invasive characteristics (Fig. 2B) and secreted 
higher amounts of MMP-9 metalloproteinase (Supplementary Fig. S2). 4T1m cells, on the other hand, exhibited 
a similar proliferative capacity (Supplementary Fig. S1), but were more invasive than parental 4T1 cells (Fig. 2B). 
A non-invasive MCA3D mouse keratinocyte cell line was included in these assays as a control. 4T1t and 4T1m 
cells were also more tumorigenic than 4T1 upon re-injection into mice. Since 4T1 cells are already strongly tum-
origenic, only 103 cells were inoculated per site into recipient animals in order to compare the tumor initiating 
capacity of each cell line. All mice inoculated with 4T1t and 4T1m cells developed tumors of 0.021–0.063 cm3 at 
13 days post-injection, whereas only 2 out of 3 mice inoculated with 4T1 cells harbored tumors of smaller vol-
umes (Fig. 2C,D). Interestingly, tumors induced by 4T1t cells grew more rapidly than those induced by 4T1 and 
4T1m cells (Fig. 2C), in light of its lower proliferative capacity in vitro.
Since 4T1m and 4T1t cells showed a more fibroblastic appearance compared to 4T1 cells, we assessed the 
expression of differentiation protein markers by Western blotting. Both 4T1m and 4T1t cells showed reduction 
of epithelial markers, such as E-cadherin, β-catenin and cytokeratin 5 (CK5). Conversely, these cells showed 
increased expression of vimentin, a mesenchymal marker (Fig. 3A). A loss of variant isoforms of the hyaluronan 
receptor CD44 (CD44v) and increased expression of the standard isoform, CD44s, was also observed in these 
cells (Fig. 3A). This shift in CD44 expression has also been related to EMT20, 21. A quantification of these changes 
by densitometric analysis is shown in Supplementary Fig. S3. Interestingly, the observed changes in differen-
tiation markers correlated with enhanced expression of the transcription factors Twist 1/2 (Fig. 3A) and Zeb1 
(Fig. 3B), two master regulators of EMT22, and with enhanced activity/autophosphorylation of Src while the total 
levels of Src were unchanged (Fig. 3A).
Since EMT has been associated with the generation of stem-like characteristics23, 24, we also analyzed the 
expression of stemness-related factors by real-time qRT-PCR. As shown in Fig. 3B, the expression of Hes1, 
Sox2 and Oct3/4, three transcription factors involved in the maintenance and self-renewal of stem cells25–27, 
was increased in both 4T1m and 4T1t cell lines (particularly in the latter) with respect to 4T1 parental cells. In 
addition, we analyzed the expression of CD44 and CD24 by flow cytometry. These two cell-surface markers have 
been associated with breast cancer stem cells (CSCs), specifically the CD44high/CD24median/low subpopulation23. 
Figure 2. Cell lines derived from 4T1-induced tumors are more malignant. (A) Origin and phase contrast 
micrographs of 4T1t and 4T1m cell lines. Bars, 100 μm. Insets show increased magnifications of the indicated 
areas. (B) Matrigel invasion assay. Cells were seeded on a 24-well Matrigel-coated invasion chamber. FBS (5%) 
was used as a chemoattractant. Migrated cells on the underside of the filter were fixed, stained and counted. 
Values are the percentage of migrated cells with respect to the total cells seeded on the well, and represent 
the means of triplicate assays from three independent experiments. Asterisks indicate statistically significant 
difference (*p < 0.05; **p < 0.01; ***p < 0.001) (C) Tumorigenic behavior of 4T1-derived cell lines. Groups of 
mice (n = 3) were inoculated i.d./s.c. with 103 cells into the left flank. The size of tumors was measured at the 
indicated times with a caliper and the volume calculated as indicated in Materials and Methods. Asterisks 
indicate statistically significant difference (**p < 0.01; ***p < 0.001). (D) The incidence of tumors at different 
indicated post-injection times.
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CD44high/CD24med/low were enhanced 2–3 fold in 4T1m and 4T1t cells with respect to the parental cell line 
(Fig. 3C), indicating enrichment in CSC-like cells.
Overall, these results suggested that 4T1-induced tumors select cells that undergo an EMT associated with 
increased tumorigenic and stem characteristics and activation of the cytoplasmic tyrosine kinase Src.
Transplantation in vivo of 4T1 cells reduces Qa-2 expression. The expression of Qa-2 was also 
analyzed in 4T1 and 4T1-derived cell lines by flow cytometry. We found that cell-surface Qa-2 expression was 
reduced approximately 2–3 fold in 4T1m and 4T1t cells with respect to 4T1 cells (Fig. 4A). In order to analyze 
the relationship of Qa-2 with stemness, we isolated the CD44high/CD24med/low cell population from 4T1m cells by 
fluorescence-activated cell sorting (FACS) and assessed the presence of Qa-2 in these cells. As shown in Fig. 4B, 
Qa-2 expression in CD44high/CD24med/low cells was negligible. This finding was confirmed by immunofluorescence 
analysis (Fig. 4C), suggesting an inverse relationship between Qa-2 expression and stem-like cells in breast cancer. 
In addition, the results obtained in this cell model indicate an inverse correlation between Qa-2 levels and tumor 
progression.
Inhibition of Src stimulates Qa-2 expression. Since the Src family kinases (SFKs) has been involved 
in EMT28, 29 and pluripotency30, and Qa-2 appears to mediate activation of the SFK member Fyn31, we treated 
4T1m and 4T1t cell lines with two well-established inhibitors of SFK activity: Dasatinib and PP232. Dasatinib 
at a concentration of 100 nM had an apparent cytotoxic effect on the cultures, causing a high proportion of cell 
death in both cell lines. In contrast, PP2 at 5 μM was more benign inducing much lower cell death (Fig. 5A 
and Supplementary Fig. S4), and promoted a reduction in the number of stringent cells, particularly in 4T1t 
cells (Supplementary Fig. S4). Both inhibitors reduced 4T1t and 4T1m cell growth, although the effect on 
4T1t cells was stronger (Fig. 5B). PP2 efficiently reduced Src activity in 4T1t cells, as shown by decreased lev-
els of phospho-Src. This effect occurred concomitantly with a slight increase in the synthesis of E-cadherin 
and β-catenin and a reduction of vimentin and Twist1/2 protein levels (Fig. 5C and Supplementary Fig. S5). 
Similar results were obtained in 4T1m cells treated with the kinase inhibitor (Supplementary Fig. S6). PP2 also 
induced a clear increase of about 2 fold in the levels of Qa-2, as assessed by real-time qRT-PCR determination 
of Q7/Q9 transcripts, two members of the Qa-2 family (Fig. 5D). In addition, we analyzed the effect of PP2 on 
stemness-related factors by Western blotting. While antibodies used for Hes1 and Oct3/4 did not recognize any 
specific protein in the cell lysates, we found that PP2 induced a decrease on the levels of Sox2, more evident in 
4T1m cells (Fig. 6A). Moreover, a reduction in the CD44high/CD24med/low cell subpopulation was also observed in 
4T1t and 4T1m cell lines after treatment with PP2 (Fig. 6B).
Qa-2 overexpression induces a less aggressive tumor phenotype. In order to evaluate the effect of 
Qa-2 modulation on tumor growth and metastasis in vivo, 4T1 cells-expressing luciferase were stably transfected 
with Q7 cDNA cloned in the pcDNA3 expression vector. Enhanced expression of Q7 in 4T1-Q7 transfectants 
Figure 3. 4T1 cells transplanted in vivo undergo a partial EMT and acquire stem-like cell characteristics. (A) 
Western blot analysis of EMT protein markers and Src. Active Src (p-Src) was detected with a mAb specifically 
recognizing Src phosphorylated on Y418. β-actin was used as a control for protein loading. The blot shown is 
representative of two independent experiments. (B) Analysis of mRNA expression of the indicated transcription 
factors. Normalized transcript levels were measured by real-time qRT-PCR relative to hprt mRNA levels. Values 
(mean of duplicate determinations) represent increases with respect to 4T1 parental cells, which were given an 
arbitrary value of 1. (C) Flow cytometry analysis of the cell-surface markers CD44 and CD24 in the indicated 
cell lines. The percentage of CD44high/CD24med/low cell subpopulation is indicated. A representative experiment 
out of two is shown.
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with respect to control 4T1-neo cells (transfected with the vector alone) was confirmed by semi-quantitative 
RT-PCR (Fig. 7A), real-time qRT-PCR (Fig. 7B), flow cytometry (Fig. 7C) and immunofluorescence (Fig. 7D) 
analysis. Overexpression of Q7 in 4T1 cells did not induce a significant morphological change or variations in the 
expression of differentiation protein markers, as determined by Western blotting (data not shown).
4T1-Q7 and 4T1-neo cells were orthotopically injected into the mammary fat pad of Balb/c mice and tumor 
growth monitored at different times by in vivo imaging. 4T1-Q7 cells induced tumors that grew slower than those 
induced by 4T1-neo cells (Fig. 8A,B). At the end of the experiment (28 days post-injection), tumor volumes 
(determined by caliper measurements) induced by 4T1-Q7 were appreciably less than those induced by control 
4T1-neo cells, although differences were not statistically significant (Fig. 8C). Strikingly, 4T1-Q7 cells were less 
metastatic than control 4T1-neo (Fig. 8A, arrows) or 4T1 parental (data not shown) cells. In fact, only about 30% 
of mice inoculated with 4T1-Q7 cells developed lung metastases versus 100% of 4T1-neo mice (Fig. 8D). The 
presence of metastatic cells in the lungs was confirmed by luciferase immunostaining of histological sections. 
Shown in Fig. 8E is a representative image of a lung section from a mouse injected with 4T1-neo cells, where a 
large number of metastatic tumor cells can be observed, whereas no metastatic tumor cells can be seen in a lung 
section from a mouse injected with 4T1-Q7 cells.
Discussion
In this study, we show that Qa-2 protein levels diminish during the growth of tumors produced in vivo by highly 
tumorigenic 4T1 breast cancer cells in syngeneic mice. Furthermore, cell lines established from 4T1-induced 
tumors (either in the back or in the mammary fat pad) showed a marked reduction in Qa-2 cell-surface expres-
sion. These cell lines, 4T1t and 4T1m, had stronger tumor initiating and invasive capacities compared to 4T1 
cells, and elicited an EMT associated with upregulation of EMT-promoting transcription factors; i.e., Twist1/2 
and Zeb122, as well as factors related to stemness, such as Hes1, Sox2 and Oct3/425–27. These results are in agree-
ment with previous reports suggesting that EMT generates cells that acquire malignant and stem-like traits23, 24. 
Likewise, we isolated a CD44high/CD24med/low cell population from 4T1m cells, which are enriched in breast 
CSCs23, 33, 34, in order to study the potential link between Qa-2 and CSCs. We found that CD44high/CD24med/low 
cells do not express Qa-2. To our knowledge, this is the first time that exclusion of the MHC class 1b proteins 
from CSCs is reported. The above results suggested an anti-tumor role for Qa-2. This assumption was confirmed 
by forcing the expression of Q7, a key member of the Qa-2 family in Balb/c mice13, 35, on the surface of 4T1 cells 
by cDNA transfection. 4T1-Q7 cells induced tumors that grew slower and produced less lung metastases than 
control or parental cells.
The anti-oncogenic role of Qa-2 is in deep contrast with the reported pro-tumorigenic function for HLA-G2, 5 
(see also the Introduction), which raises the question whether Qa-2 is the functional murine homolog of HLA-G, 
at least in the context of cancer. Our results are in line with studies reported by Chiang and Stroynowski on 
the protective role exerted by Q9 for melanoma, lung carcinoma and T-cell lymphoma in vivo outgrowth. In 
Figure 4. Cell lines derived from 4T1 tumors have reduced Qa-2 expression. (A) Analysis of Qa-2 cell-surface 
expression by flow cytometry. (B) The CD44high/CD24med/low cell subpopulation was isolated from 4T1m 
cells by FACS and the expression of Qa-2 determined in these cells (bottom panel) and in the total 4T1m 
cell population (upper panel). Note that Qa-2 expression in CD44high/CD24med/low cells is undetectable. (C) 
Immunofluorescence detection of Qa-2 in 4T1m and CD44high/CD24med/low cells. Nuclei were stained with 
DAPI. Bars, 100 μm. Insets show increased magnifications of the indicated areas.
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these studies, restoration of Q9 expression in tumors that have downregulated Q9 results in a CD8+ cytotoxic 
T lymphocytes (CTL)-mediated response that eliminates them in syngeneic hosts14–16. In other report, the same 
authors have shown that Q9 expressed in class I-deficient melanoma cells protects cells from NK cell-mediated 
cytolysis36. In this respect, Qa-2 exclusion from CD44high/CD24med/low cells might be related to immune evasion 
of this breast CSC-like cell subpopulation, a hypothesis that remains to be investigated. Indeed, when mice were 
challenged with 4T1 cells overexpressing Q7 on their surface tumors that developed grew at a slower rate and 
were less aggressive than those induced by control cells, which might suggest that Q7 renders tumors suscepti-
ble to immune surveillance; hence, downregulation of Qa-2 during in vivo 4T1 tumor growth. Alternatively, an 
immune-independent mechanism might be behind the anti-tumorigenic effect of Q7, as 100% of mice challenged 
with 4T1-Q7 cells developed tumors as did mice challenged with control 4T1-neo cells. Further work is needed 
to clarify this issue.
We also provide evidence in this study that Src signaling negatively regulates Qa-2 expression in breast 
cancer cells, as inhibition of Src activity by the well-established PP2 inhibitor enhanced Qa-2 transcript levels. 
Interestingly, patients with triple negative breast cancer appear to be sensitive to treatment with pharmacological 
inhibitors of Src37. The PP2-mediated increase in Qa-2 expression levels occurred concomitantly with a reduction 
in Sox2 expression and the number of CD44high/CD24med/low cells, emphasizing again the inverse relationship 
between Qa-2 and stemness in breast cancer cells. Also, PP2 induced a slight reversion of EMT, as shown by 
decreased expression of Twist1/2 and vimentin and an observable increase in E-cadherin and β-catenin levels. 
These results suggest at least a partial role for Src activity in the enrichment of CSC cells and EMT induced by 
transplantation of 4T1 cells in vivo. Augmented Src activity has been found in several types of malignancies, 
including breast cancer, associated not only with increased tumor cell proliferation, but also with EMT, invasion 
and metastasis28, 29.
Figure 5. Pharmacological inhibition of Src enhances Qa-2 expression. (A) Effect of Src inhibitors on cell 
viability. 4T1t and 4T1m cell cultures were treated with Dasatinib (Dasa; 100 nM) and PP2 (5 μM) for 48 h, and 
cell viability was determined by Trypan blue exclusion. Values represent the means of duplicate incubations. (B) 
Effect of Src inhibitors on cell growth. Cultures were treated as specified in panel A, and cells were counted at 
the end of the experiment. (C) Effect of PP2 (5 μM) on the expression of Src and EMT protein markers of 4T1t 
cells. Protein levels were determined by Western blot analysis. β-actin was used as a control for protein loading. 
(D) Analysis of Q7/Q9 mRNA expression. Transcript levels were measured by real-time qRT-PCR, normalized 
to β-actin mRNA levels, and values for PP2-treated cells were compared to untreated cells, which were given an 
arbitrary value of 1.
www.nature.com/scientificreports/
7SCIEnTIFIC REPORTS | 7: 6276 | DOI:10.1038/s41598-017-06528-x
In summary, we show in this report an inverse relationship between Qa-2 expression and malignancy, 
epithelial-mesenchymal transition and stemness in breast cancer that appears to be partially mediated by Src 
signaling. However, more studies are necessary to unveil the mechanism(s) behind these connections, and to 
decipher the exact role of Qa-2 in malignancy.
Materials and Methods
Cell culture and treatments. The 4T1 cell line was obtained from the American Type Culture Collection 
(ATCC, USA). 4T1m and 4T1t cell lines were derived by explanting tumors induced by 4T1 cells in the mammary 
fat pad (see below) and the back (i.d./s.c.) of Balb/cj mice, respectively. Tumors had a size 0.5–1 cm-diameter 
when explanted. MCA3D are non-tumorigenic keratinocytes derived from mouse skin treated with a chem-
ical carcinogen38. Cell lines were routinely cultured in Dulbecco’s modified Eagle’s medium (DMEM), except 
MCA3D cells that were grown in Ham’s F-12 medium, supplemented with 1% penicillin/streptomycin and 10% 
fetal bovine serum (FBS; Gibco), at 37 °C, in a humidified 5% CO2 atmosphere. All cell lines were tested for myco-
plasma contamination by immunofluorescence staining with 1 μg/ml solution of 4′,6-diamino-2-phenilindole 
(DAPI; Sigma–Aldrich).
Cells were treated with Src family kinase inhibitors Dasatinib (100 nM) and PP2 (5 μM), as previously 
described32. Briefly, ~ 6 × 105 cells were seeded in duplicate plates, and incubated in the presence of inhibitors 
for 48 h. At the end of the experiment, cells were counted and the percentage of growth inhibition calculated with 
respect to vehicle-treated controls. Cell viability was determined by 0.4% Trypan blue exclusion.
cDNA transfection. The H2-Q7 antigen full-length coding sequence was amplified by PCR using the 
following primers: forward: 5′-CAGTGTGCTGGAATTCATGGCTCTAACAATGCTGCTC-3′, and reverse: 
5′-GATATCTGCAGAATTCCCACCTGTGTTTCACCTCCTA-3′, and the Phusion® High Fidelity DNA poly-
merase (New England Biolabs). The PCR product was subcloned into the pcDNA3 expression vector (Invitrogen) 
with In-Fusion HD Cloning kit (Clontech). The presence and integrity of the insert was verified by DNA sequenc-
ing. 4T1 cells were transfected with this plasmid, or the pcDNA3 vector alone (control), using Lipofectamine 
2000 (Invitrogen), and transfected cells selected in 0.5 mg/ml G418 (Invitrogen) for 3 weeks.
Matrigel invasion assay. Invasion assays were performed using Transwell chambers with 8-μm-pore poly-
carbonate filters coated with Matrigel (BD Biosciences). Approximately 2 × 104 cells were seeded in the upper 
compartment in medium without serum, and allowed to transmigrate for 24 h using 5% FBS as a chemoattractant 
Figure 6. Pharmacological inhibition of Src reduces stemness. (A) Western blot analysis of Sox2 expression 
in 4T1m and 4T1t cells untreated or treated with PP2. Due to the high background observed in the blot, a 
positive control with a lysate of 293 T cells overexpressing Sox2 (c) was included. β-actin was used as a control 
for protein loading. (B) Flow cytometry analysis of the cell-surface markers CD44 and CD24 in 4T1m and 4T1t 
cells untreated or treated with PP2. The percentage of CD44high/CD24med/low cell subpopulation is indicated. A 
representative experiment out of two is shown.
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in the bottom compartment. Non-migrated cells on the upper side of the Transwell were subsequently removed, 
and those on the underside were fixed with methanol and stained with 0.1% crystal violet. Cell migration was 
quantified by counting the number of cells that migrated through the filters. Ten different fields (x200) were 
counted in triplicate experiments.
Quantitative and semiquantitative RT-PCR. RNA from cell lines was purified using the RNeasy kit 
(Qiagen). Quantitative reverse transcription-PCR analysis was performed using the high-capacity cDNA Reverse 
Transcription kit (Applied Biosystems) in a 7900HT Fast (Life Technologies) instrument. Taqman probes for 
Qa-2 (Mm00843895_s1) and β-actin (Mm00843895_s1), used as an internal control, were purchased from Life 
Technologies. Amplification of Zeb1, Sox2, Hes1 and Oct3/4 transcription factors was performed using Power 
SYBRTM Green Master Mix (ThermoFisher), with hypoxhantine-guanine phosphoribosyl transferase (hprt) as an 
internal control. Oligonucleotide sequences for these primers are detailed in Supplementary Information.
For semiquantitative RT-PCR, RNAs (1 μg) were incubated with the Moloney murine leukemia virus reverse 
transcriptase (Promega), and the generated cDNA were used for PCR amplication. Specific primers for Q7/Q9 
and β-actin amplification have been described elsewhere13.
Western blot and ELISA analysis. For Western blot analysis, cells were lysed in RIPA buffer containing a 
cocktail of protease and phosphatase inhibitors, as described39. For immunodetection of proteins, the following 
primary antibodies (Abs) were used: mAb ECCD for E-cadherin (dilution 1:250), kindly provided by Dr A. Cano 
(Instituto de Investigaciones Biomédicas Alberto Sols, Spain), mAbs 610153 (1:2000) and RV202 (1:250) for 
β-catenin and vimentin, respectively, from BD Biosciences; mAb EPR1600Y (1:1500) for CK5 from Abcam; mAb 
327 (1:500) for Src was a kind gift of Dr. J.S. Brugge (Harvard Medical School, USA) and polyclonal Ab recogniz-
ing Src phosphorylated Y418 (1:1000) was from Biosource Int. (Invitrogen); polyclonal Ab for Twist1/2 (1:1000) 
was from Genentech; mAb AC-74 (1:10000) for β-actin from Sigma-Aldrich; mAb KM-201 (1:200) for CD44 
was a kind gift from Dr. H. Yarwood (Imperial College London, UK); and polyclonal goat IgG for Sox2 (AF2018, 
R&D Systems), a generous gift from Dr. I. Palmero (Instituto de Investigaciones Biomédicas Alberto Sols, Spain). 
Appropriate horseradish-peroxidase (HRP)-conjugated IgGs were used as secondary antibodies. Peroxidase 
activity was visualized using an enhanced chemiluminescence kit as indicated by the manufacturer (Pierce).
Figure 7. Stable transfection of Q7 cDNA into 4T1 cells. (A) Semiquantitative RT-PCR analysis of Q7 expression. 
Q7/Q9m, membrane-associated form; Q7/Q9s, soluble form. (B) Analysis of Q7 mRNA expression. Transcript 
levels were measured by real-time qRT-PCR, normalized to β-actin mRNA levels, and values for 4T1-Q7 were 
compared to 4T1-neo, which were given an arbitrary value of 1. (C) Analysis of Q7 cell-surface expression by flow 
cytometry. (D) Immunofluorescence detection of Q7. Nuclei were stained with DAPI. Bars, 100 μm.
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The concentration of Qa-2 in the sera of mice was determined using a Qa-2 ELISA kit (MyBiosource.com) 
following the manufacturer’s recommendations.
Flow cytometry and sorting. The following antibodies were used for FACS analysis: fluorescein isothiocy-
anate (FITC)-conjugated anti-CD44 (clone KM201) and anti-Qa-2 (clone 69H1–9–9, eBioscience), and phyco-
erytrin (PE)-conjugated anti-CD24 (clone M1/69, Miltenyi Biotech), in a FACS Canto II with FACSDiva software 
(BD Bioscience) or in a Cytomics FC 500 MPL with MXP software (Beckman Coulter). Positivity for Qa-2 expres-
sion was identified using mouse IgG2a kappa isotype control (FITC) (Supplementary Fig. S7). As positive control, 
C57Bl/6 mouse splenocytes were used (Supplementary Fig. S7). CD44high expression level was selected arbitrarily 
to include cells having fluorescence intensity units (FI) higher than 50. Similarly, CD24low expression level was 
selected to include cells having FI lower than 50, and CD24median expression level cells with FI between 50 and 400. 
Sorting of the CD44high/CD24med/low cell subpopulation from 4T1m cells was performed using a FACSVantage SE 
sorter (BD Biosciences).
Tumorigenicity and bioluminescence assays. All animal experiments were approved by the Animal 
Care and Use Committees of the Spanish National Research Council (CSIC), Community of Madrid (Ref. PROEX 
37/14) and Federal University of Minas Gerais of Brazil. Mice were cared for following institutional guidelines and 
in accordance with the standards established by the European Union (2010/63/UE) and the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals.
For tumorigenicity assays, 106 or 103 cells (as indicated) were i.d./s.c. injected into the left flank of 6 to 8-weeks 
old female Balb/cj mice (Harlan). The size of tumors was calculated via caliper measurements of two orthogonal 
diameters at different times. The tumor volume was calculated using the equation V = a × b2/2, where a is the 
largest diameter and b is the smallest diameter. Tumors were fixed in formalin and embedded in paraffin.
For experiments to evaluate the tumorigenic and metastatic potential of 4T1-neo and 4T1-Q7 cell lines, mice 
were anesthetized with isofluorane inhalation before orthotopic transplantation of cells. An incision of ~ 0.5 cm 
was made along the medial side of the nipple of the second right mammary gland. Approximately, 105 cells, stably 
infected with lentiviral expression particles for luciferase (CMV-Luciferase firefly, from AMSBIO, Abingdon, 
UK), were injected into the exposed fat pad, and the skin layer was subsequently closed with surgical staples. Each 
mouse was imaged periodically, using an IVIS Lumina 2 imaging system (Xenogen, USA), after retro-orbital 
injection of 3 mg luciferin (Goldbio, USA) in 100 μl of PBS under anesthesia. The areas of tumors (ROI, regions 
of interest) were determined at different post-inoculation times according to Living Image 4.0 software (Perkin 
Elmer). After 28 days, mice were euthanasized and lungs excised for immunofluorescence analysis. Pieces of lungs 
were fixed in formalin and embedded in paraffin.
Figure 8. Overexpression of Q7 reduces tumor growth and metastatic potential of 4T1 cells. (A) Representative 
whole body bioluminescence images of mice with tumors induced by the indicated cell lines at 15 and 28 
days post-injection. Note that 4T1-neo, but not 4T1-Q7 mice show metastatic colonies at 28 days (arrows). 
(B) Tumor growth was monitored at different post-injection days by measuring the bioluminescence area 
as indicated in Materials and methods. Asterisks indicates statistically significant differences (*p < 0.05; 
**p < 0.01). (C) Measurement of the volumes of primary tumors at 28 days post-inoculation. n.s., statistically 
non-significant. (D) Incidence of pulmonary metastases at 28 days post-inoculation. (E) Immunofluorescence 
detection of luciferase in lungs of mice with mammary tumors induced by 4T1-neo and 4T1-Q7 cells at 28 days 
post-injection. Nuclei were stained with DAPI. Bars, 100 μm.
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Immunohistochemical and immunofluorescence analysis. Immunohistochemical detection of Qa-2 
was performed in deparaffinized tumor sections, after heat-induced antigen retrieval, by the Envision plus per-
oxidase method (Dako). Clone 69H1-9-9 (1:50) was used as the primary Ab for Qa-2 detection. The reaction 
product was developed with diaminobenzidine tetrahydrochloride and H2O2. The sections were dehydrated in 
graded ethanols, cleared in xylene, and mounted in Permont after counterstain with Hematoxylin. A total number 
of 15 sections (x60) were evaluated. Workshop score for Qa-2 expression in tumor cells was as follows: + 1 when 
up to 10% of cells were stained; +2 when 11–25% of cells were stained; and +3 when > 25% of cells were stained.
Immunofluorescence detection of Qa-2 in cultured cells was performed in confluent cultures grown on glass 
coverslips, washed in PBS and permeabilized with 0.05% Triton X-100, using FITC-conjugated anti-Qa-2 mAb 
(clone 69H1-9-9, 1:50; eBioscience). Coverslips were mounted on ProLong® Diamond Antifade Mountant with 
DAPI (Thermo Fisher Scientific) and examined with a fluorescence microscope (Nikon Eclipse 90i).
For immunolocalization of luciferase in deparaffinized lung histological sections, a goat polyclonal Ab against 
luciferase (1:100; Novus Biologicals) was used after permeabilization in 0,1% Triton X-100 and heat-induced 
antigen retrieval in 1 mM EDTA. The primary Ab signal was amplified using donkey anti-goat IgG secondary 
Ab coupled to HRP and TSA Plus Cyanine (Perkin Elmer), following the manufacturer’s instructions. Cell nuclei 
were counterstained with DAPI.
Statistics. The data are shown as the mean ± SEM. All data were normalized by Kolmogorov-Smirnov test 
and Grubbs’ test for outliers. Comparison between two groups was performed using the Student’s t test and for 
unpaired data by the Mann-Whitney U test. Significance was determined using the one-way analysis of variance 
(ANOVA) or the Student’s t test. Differences were considered significant if P < 0.05. All statistical analyses was 
performed using GraphPad Instat 5.0 software.
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